<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>9(1)</volume><submitter>Chen H</submitter><pubmed_abstract>Hemophilia A is a monogenic disease with a blood clotting factor VIII (FVIII) deficiency caused by mutation in the factor VIII (F8) gene. Current and emerging treatments such as FVIII protein injection and gene therapies via AAV-delivered F8 transgene in an episome are costly and nonpermanent. Here, we describe a CRISPR/Cas9-based in vivo genome editing method, combined with non-homologous end joining, enabling permanent chromosomal integration of a modified human B domain deleted-F8 (BDD-F8) at the albumin (Alb) locus in liver cells. To test the approach in mice, C57BL/6 mice received tail vein injections of two vectors, AAV8-SaCas9-gRNA, targeting Alb intron 13, and AAV8-BDD-F8. This resulted in BDD-F8 insertion at the Alb locus and FVIII protein expression in the liver of vector-, but n</pubmed_abstract><journal>Scientific reports</journal><pagination>16838</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC6856096</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Hemophilia A ameliorated in mice by CRISPR-based in vivo genome editing of human Factor VIII.</pubmed_title><pmcid>PMC6856096</pmcid><pubmed_authors>Gilam A</pubmed_authors><pubmed_authors>Shi M</pubmed_authors><pubmed_authors>Li J</pubmed_authors><pubmed_authors>Afrikanova I</pubmed_authors><pubmed_authors>Gluzman Z</pubmed_authors><pubmed_authors>Zhang Y</pubmed_authors><pubmed_authors>Jiang R</pubmed_authors><pubmed_authors>Zheng Q</pubmed_authors><pubmed_authors>Chen H</pubmed_authors><pubmed_authors>Kong LJ</pubmed_authors><pubmed_authors>Chen-Tsai RY</pubmed_authors></additional><is_claimable>false</is_claimable><name>Hemophilia A ameliorated in mice by CRISPR-based in vivo genome editing of human Factor VIII.</name><description>Hemophilia A is a monogenic disease with a blood clotting factor VIII (FVIII) deficiency caused by mutation in the factor VIII (F8) gene. Current and emerging treatments such as FVIII protein injection and gene therapies via AAV-delivered F8 transgene in an episome are costly and nonpermanent. Here, we describe a CRISPR/Cas9-based in vivo genome editing method, combined with non-homologous end joining, enabling permanent chromosomal integration of a modified human B domain deleted-F8 (BDD-F8) at the albumin (Alb) locus in liver cells. To test the approach in mice, C57BL/6 mice received tail vein injections of two vectors, AAV8-SaCas9-gRNA, targeting Alb intron 13, and AAV8-BDD-F8. This resulted in BDD-F8 insertion at the Alb locus and FVIII protein expression in the liver of vector-, but n</description><dates><release>2019-01-01T00:00:00Z</release><publication>2019 Nov</publication><modification>2025-04-19T09:52:54.525Z</modification><creation>2020-05-21T19:13:08Z</creation></dates><accession>S-EPMC6856096</accession><cross_references><pubmed>31727959</pubmed><doi>10.1038/s41598-019-53198-y</doi></cross_references></HashMap>